Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | GAPDH | P04406 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19887050 | 1.00 | ADORA1 (0.48) | ADORA1GAAEHMT1ADORA3SMN1; SMN2 | |
| SCHEMBL19522864 | 0.90 | ADORA3 (0.51) | ADORA1GAAEHMT1ADORA3SMN1; SMN2 | |
| SCHEMBL15280867 | 0.90 | ADORA3 (0.51) | ADORA1GAAEHMT1ADORA3SMN1; SMN2 | |
| SCHEMBL19887015 | 0.90 | ADORA3 (0.51) | ADORA1GAAEHMT1ADORA3SMN1; SMN2 | |
| SCHEMBL19887054 | 0.86 | ADORA1 (0.53) | ADORA1 | |
| SCHEMBL15280876 | 0.86 | ADORA1 (0.51) | ADORA1SMN1; SMN2DNPH1PRKAB2TRPM2 | |
| SCHEMBL15280856 | 0.86 | ADORA1 (0.53) | ADORA1 | |
| SCHEMBL19887049 | 0.86 | ADORA1 (0.51) | ADORA1SMN1; SMN2DNPH1PRKAB2TRPM2 | |
| SCHEMBL19522845 | 0.84 | ADORA1 (0.60) | ADORA1EHMT1ADORA3SMN1; SMN2DPP4 | |
| SCHEMBL19887063 | 0.84 | ADORA1 (0.60) | ADORA1EHMT1ADORA3SMN1; SMN2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018516-A1 | Agent for Regulating Expression and/or Function of RPS25 Gene | Sumitomo Pharma Co., Ltd. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
| US-8987226-B2 | Modified single-stranded polynucleotides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20130253038-A1 | Modified Single-Stranded Polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257951-A1 | NOVEL LIPID | NPC1L1, CETP, LIPC | ADORA1 1034/4885GAA 944/4885EHMT1 3655/4885 |
| US-20240018516-A1 | Agent for Regulating Expression and/or Function of RPS25 Gene | RPS25, RPS26, RPS24 | ADORA1 4048/4885GAA 1841/4885EHMT1 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.